NCT00051831 - Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

December 31, 2007

Study Completion Date

May 31, 2008

Conditions

HIV Infections

Interventions

DRUG

Emtricitabine

Will be administered as one 200-mg capsule orally daily

DRUG

Enfuvirtide

Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily

DRUG

Ritonavir

Will be administered as one 100-mg capsule orally twice daily

DRUG

Saquinavir

Will be administered as five hard gel capsules orally twice daily

DRUG

Tenofovir disoproxil fumarate

Will be administered as one 300-mg tablet orally daily

Trial Locations (7)

27514

Unc Aids Crs, Chapel Hill

80262-3706

University of Colorado Hospital CRS, Aurora

02114

Massachusetts General Hospital ACTG CRS, Boston

63108-2138

Washington U CRS, St Louis

10016-6481

NY Univ. HIV/AIDS CRS, New York

Unknown

The Ohio State Univ. AIDS CRS, Columbus

00936-5067

Puerto Rico-AIDS CRS, San Juan

All Listed Sponsors

collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH